Major depressive disorder treatment guidelines in America and Europe - PubMed (original) (raw)
Comparative Study
Major depressive disorder treatment guidelines in America and Europe
Jonathan R T Davidson. J Clin Psychiatry. 2010.
Abstract
The various major American and European guidelines for the treatment of depression provide similar basic principles of treatment, which include individualizing the treatment plan, preparing the patient for potential long-term treatment, providing measurement-based care, and treating to remission. While the guidelines are all evidence-based, certain factors can influence differences in specific recommendations, such as the consensus group's composition, underlying mandates, and cultural attitudes. The similarities and differences among 6 sets of guidelines from Europe and the Americas published in the past decade are reviewed here (American Psychiatric Association, British Association for Psychopharmacology, Canadian Network for Mood and Anxiety Treatments, National Institute for Health and Clinical Excellence, Texas Medication Algorithm Project, and World Federation of Societies of Biological Psychiatry). In the guidelines, mild depression has the most variance in treatment recommendations; some, but not all, guidelines suggest that it may resolve with exercise or watchful waiting, but psychotherapy or antidepressants could be used if initial efforts fail. Moderate and severe major depression carry broadly similar recommendations among the guidelines. First-line treatment recommendations for moderate major depressive disorder include antidepressant monotherapy, psychotherapy, and the combination of both. Severe depression may require the combination of an antidepressant and an antipsychotic, electroconvulsive therapy, or the combination of an antidepressant and psychotherapy. Benzodiazepines play a very limited role in the treatment of depression; if the patient has catatonic depression, acutely suicidal depression, or depression with symptoms of anxiety, agitation, or insomnia, benzodiazepines are recommended by some guidelines for short-term treatment only.
Similar articles
- Major depressive disorder treatment guidelines in Japan.
Higuchi T. Higuchi T. J Clin Psychiatry. 2010;71 Suppl E1:e05. doi: 10.4088/JCP.9058se1c.05gry. J Clin Psychiatry. 2010. PMID: 20371032 - International consensus statement on major depressive disorder.
Nutt DJ, Davidson JR, Gelenberg AJ, Higuchi T, Kanba S, Karamustafalioğlu O, Papakostas GI, Sakamoto K, Terao T, Zhang M. Nutt DJ, et al. J Clin Psychiatry. 2010;71 Suppl E1:e08. doi: 10.4088/JCP.9058se1c.08gry. J Clin Psychiatry. 2010. PMID: 20371035 - Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication.
Parikh SV, Segal ZV, Grigoriadis S, Ravindran AV, Kennedy SH, Lam RW, Patten SB; Canadian Network for Mood and Anxiety Treatments (CANMAT). Parikh SV, et al. J Affect Disord. 2009 Oct;117 Suppl 1:S15-25. doi: 10.1016/j.jad.2009.06.042. Epub 2009 Aug 13. J Affect Disord. 2009. PMID: 19682749 - A review of the current guidelines for depression treatment.
Gelenberg AJ. Gelenberg AJ. J Clin Psychiatry. 2010 Jul;71(7):e15. doi: 10.4088/JCP.9078tx1c. J Clin Psychiatry. 2010. PMID: 20667285 Review. - Major depressive disorder treatment guidelines in China.
Zhang M. Zhang M. J Clin Psychiatry. 2010;71 Suppl E1:e06. doi: 10.4088/JCP.9058se1c.06gry. J Clin Psychiatry. 2010. PMID: 20371033
Cited by
- Integrating network pharmacology and bioinformatics to explore the mechanism of Xiaojian Zhongtang in treating major depressive disorder: An observational study.
Jiang H, Zhang J, Li Q, Zhou Y. Jiang H, et al. Medicine (Baltimore). 2024 Sep 20;103(38):e39726. doi: 10.1097/MD.0000000000039726. Medicine (Baltimore). 2024. PMID: 39312335 Free PMC article. - Nanocarrier drug delivery system: promising platform for targeted depression therapy.
Feng X, Jia P, Zhang D. Feng X, et al. Front Pharmacol. 2024 Jul 25;15:1435133. doi: 10.3389/fphar.2024.1435133. eCollection 2024. Front Pharmacol. 2024. PMID: 39119603 Free PMC article. Review. - Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis.
Raja A, Ahmed S, Basit Ali Siddiqui M, Lamiya Mir S, Kumar R, Ahmed M, Raja S, Bin Amin S, Alim Ur Rahman H, Deepak F, Asghar MS. Raja A, et al. Front Psychiatry. 2024 Jul 5;15:1425295. doi: 10.3389/fpsyt.2024.1425295. eCollection 2024. Front Psychiatry. 2024. PMID: 39035602 Free PMC article. - Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers CH, Kupka RW, Penninx BW, Ruhé HG, van Gaalen JM, van Haaren PCF, Schellekens AFA, Jauhar S, Ramos-Quiroga JA, Vieta E, Tiihonen J, Veldman SE, Veling W, Vis R, de Wit LE, Luykx JJ. Vinkers CH, et al. Mol Psychiatry. 2024 Aug;29(8):2575-2586. doi: 10.1038/s41380-024-02445-4. Epub 2024 Mar 19. Mol Psychiatry. 2024. PMID: 38503923 Free PMC article. Review. - Knowledge, attitude, and practice of patients with major depressive disorder on exercise therapy.
Cheng J, Feng Y, Liu Z, Zheng D, Han H, Liu N, Liu S, Zhao J, Li X, Han S. Cheng J, et al. BMC Public Health. 2024 Jan 29;24(1):323. doi: 10.1186/s12889-024-17821-6. BMC Public Health. 2024. PMID: 38287298 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous